• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Three Biosimilars on the Market and Hadlima To Come

Video

Samsung Bioepis executive Tom Newcomer’s touts the 10-year-old biosimilar company’s achievements as it gets ready to launch its Humira biosimilar, Hadlima.

Fourth of four parts

Tom Newcomer, head of U.S. market access for Samsung Bioepis, talks about his company’s track record during this final segment of his interview with Tony Hagen, a freelance writer and a regular contributor Managed Healthcare Executive

Newcomer talks to Hagen about the three biosimilars that the company has on the market as well as Hadlima (adalimumab-bwwd), the Humira biosimilar that is planning to launch next year.

The three Samsung Bioepis biosimilars already on the market are Byooviz (ranibizumab-nuna), a biosimilar to Lucentis that Biogen is marketing in the U.S.;Renflexis (infliximab-abda), a biosimilar to Remicade; and Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin. Organon, a Jersey City, New Jersey, company is marketing Hadlima, Renflexis and Ontruzant for Samsung Bioepis in the U.S.

Newcomer notes that Byooviz is the first ophthalmic biosimilar; it is FDA-approved as treatment for wet age-related macular degeneration and other eye diseases. He also mentions that Ontruzant as now having five years of data behind it.

Related Videos
"Payer-Provider Collaboration Driving Biosimilar Utilization"
Biosimilar K-Cast - "Overcoming Challenges Associated with Biosimilars"
Biologics video - "The Benefit Channel" Pharmacy Benefits and Medical Benefits
Related Content
© 2024 MJH Life Sciences

All rights reserved.